Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-01-06

Clinical Trial Update: Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) [Phase 2]

View source ↗

Summary

Phase 2 study of ANX005 in adults with amyotrophic lateral sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ANX005

Snippet

Sponsor: Annexon, Inc. | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED